Research Team

Jacob Borodovsky, PhD

Associate Professor, The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth

Opioids; Buprenorphine; Marijuana; Cannabis; Epidemiology; Policy


Contact

Jacob Borodovsky, PhD
Associate Professor, The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth

46 Centerra Parkway, Suite 300-301
, Lebanon, NH 03766

Jacob.T.Borodovsky@dartmouth.edu


Selected Publications
  • Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat. 2014 Sep;47(3):202-12. doi: 10.1016/j.jsat.2014.04.006. PMID: 24953168; PMCID: PMC4180514.
  • Schuman-Olivier Z, Connery H, Griffin ML, Wyatt SA, Wartenberg AA, Borodovsky J, Renner JA Jr, Weiss RD. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013 Nov-Dec;22(6):574-80. doi: 10.1111/j.1521-0391.2013.12024.x. PMID: 24131165; PMCID: PMC3801272.
  • Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ. Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes. Drug Alcohol Depend. 2013 Oct 1;132(3):580-6. doi: 10.1016/j.drugalcdep.2013.04.006. PMID: 23688843; PMCID: PMC3916951.